Intracellular drug delivery in Leishmania-infected macrophages: Evaluation of saponin-loaded PLGA nanoparticles

Journal of Drug Targeting

Volumn 20, Issue 2, 2012, Pages 142-154

  Van De Ven, H ^a   Vermeersch, M ^a   Vandenbroucke, R E ^b   Matheeussen, A ^a   Apers, S ^a   Weyenberg, W ^a   De Smedt, S C ^b   Cos, P ^a   Maes, L ^a   Ludwig, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Co localisation; GFP transfected L. donovani; J774A.1 macrophages; Leishmaniasis; PLGA nanoparticles; Saponins; Simplex mixture design

Indexed keywords

BETA ESCIN; NANOPARTICLE; POLYGLACTIN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; EMULSIFICATION SOLVENT EVAPORATION; EX VIVO STUDY; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; SALTING OUT TECHNIQUE; SYRIAN HAMSTER; ZETA POTENTIAL;

ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; ESCIN; LACTIC ACID; LEISHMANIA INFANTUM; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 80054682264     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.595491     Document Type: Article

References (72)

1. Adler-Moore JP, Proffitt RT. (2008). Amphotericin B lipid preparations: What are the differences? Clin Microbiol Infect, 14 Suppl 4, 25-36. (Pubitemid 351593914)
2. Apers S, Naessens T, Pieters L, Vlietinck A. (2006). Densitometric thin-layer chromatographic determination of aescin in a herbal medicinal product containing Aesculus and Vitis dry extracts. J Chromatogr A, 1112, 165-170.
3. Barak E, Amin-Spector S, Gerliak E, Goyard S, Holland N, Zilberstein D. (2005). Differentiation of Leishmania donovani in host-free system: Analysis of signal perception and response. Mol Biochem Parasitol, 141, 99-108. (Pubitemid 40461901)
4. Bareford LM, Swaan PW. (2007). Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev, 59, 748-758. (Pubitemid 47320813)
5. Beck-Broichsitter M, Rytting E, Lebhardt T, Wang X, Kissel T. (2010). Preparation of nanoparticles by solvent displacement for drug delivery: A shift in the "ouzo region" upon drug loading. Eur J Pharm Sci, 41, 244-253.
6. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B, Rafati S. (2011). Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol, 127, 637-645.
7. Briones E, Colino CI, Lanao JM. (2008). Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release, 125, 210-227.
8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. 2007). Visceral leishmaniasis: What are the needs for diagnosis treatment and control? Nat Rev Microbiol, 5, 873-882 (Pubitemid 47578388)
9. Chellat F, Merhi Y, Moreau A, Yahia L. (2005). Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 26, 7260-7275. (Pubitemid 41133578)
10. Cohen BE. (2010). Amphotericin B membrane action: Role for two types of ion channels in eliciting cell survival and lethal effects. J Membr Biol, 238, 1-20.
11. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. (2009). A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release, 133, 90-95.
12. Cos P, Vlietinck AJ, Berghe DV, Maes L. (2006). Anti-infective potential of natural products: How to develop a stronger in vitro 'proof-ofconcept'. J Ethnopharmacol, 106, 290-302. (Pubitemid 43949328)
13. Date AA, Joshi MD, Patravale VB. (2007). Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev, 59, 505-521. (Pubitemid 47259228)
14. Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas N, Mshvildadze V, Dekanosidze G, Kemertelidze E, Timon-David P. (2000). Antileishmanial activity of three saponins isolated from ivy, alphahederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. Planta Med, 66, 343-347. (Pubitemid 30346298)
15. Dillen K, Bridts C, Van der Veken P, Cos P, Vandervoort J, Augustyns K, Stevens W, Ludwig A. (2008). Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas. Int J Pharm, 349, 234-240.
16. Dinda B, Debnath S, Mohanta BC, Harigaya Y. (2010). Naturally occurring triterpenoid saponins. Chem Biodivers, 7, 2327-2580.
17. Douglas KL, Piccirillo CA, Tabrizian M. (2008). Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm, 68, 676-687. (Pubitemid 351318216)
18. Dube A, Gupta R, Singh N. (2009). Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol, 25, 432-439.
19. Dube A, Singh N, Sundar S, Singh N. (2005). Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res, 96, 216-223. (Pubitemid 40933669)
20. Dutta A, Ghoshal A, Mandal D, Mondal NB, Banerjee S, Sahu NP, Mandal C. (2007). Racemoside A, an anti-leishmanial, watersoluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani. J Med Microbiol, 56, 1196-1204. (Pubitemid 47477192)
21. Gaumet M, Gurny R, Delie F. (2007). Fluorescent biodegradable PLGA particles with narrow size distributions: Preparation by means of selective centrifugation. Int J Pharm, 342, 222-230. (Pubitemid 47259326)
22. Germonprez N, Maes L, Van Puyvelde L, Van Tri M, Tuan DA, De Kimpe N. (2005). In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives. J Med Chem, 48, 32-37. (Pubitemid 40105247)
23. Golenser J, Domb A. (2006). New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem, 6, 153-162.
24. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. (2007). Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun, 353, 26-32. (Pubitemid 44958337)
25. Huth US, Schubert R, Peschka-Suss R. (2006). Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J Control Release, 110, 490-504. (Pubitemid 43168188)
26. Inocencio da Luz RA, Vermeersch M, Deschacht M, Hendrickx S, Van Assche T, Cos P, Maes L. 2011. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species. J Antimicrob Chemother, 66, 350-353.
27. Inocencio da Luz R, Vermeersch M, Dujardin JC, Cos P, Maes L.2009. In vitro sensitivity testing of Leishmania clinical field isolates: Preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53 (12), 5197-203
28. Italia JL, Yahya MM, Singh D, Ravi Kumar MN. (2009). Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm Res, 26, 1324-1331.
29. Kamau SW, Grimm F, Hehl AB. (2001). Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob Agents Chemother, 45, 3654-3656. (Pubitemid 33107901)
30. Kanchan V, Panda AK. (2007). Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials, 28, 5344-5357. (Pubitemid 47532191)
31. Kayser O. (2000). Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int J Pharm, 196, 253-256. (Pubitemid 30105755)
32. Maes L, Germonprez N, Quirijnen L, Van Puyvelde L, Cos P, Vanden Berghe D. (2004). Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother, 48, 2056-2060. (Pubitemid 38691597)
33. Maes L, Germonprez N, Van Puyvelde L, Van Tri M, Ngoc Ninh T, De Kimpe N. 2000. Antiprotozoal saponins, International patent WO 00/38700.
34. Maes L, Vanden Berghe D, Germonprez N, Quirijnen L, Cos P, De Kimpe N, Van Puyvelde L. (2004). In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob Agents Chemother, 48, 130-136. (Pubitemid 38040188)
35. Mandal D, Panda N, Kumar S, Banerjee S, Mandal NB, Sahu NP. (2006). A triterpenoid saponin possessing antileishmanial activity from the leaves of Careya arborea. Phytochemistry, 67, 183-190. (Pubitemid 43005226)
36. McCarron PA, Donnelly RF, Marouf W. (2006). Celecoxib-loaded poly (D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J Microencapsul, 23, 480-498. (Pubitemid 44446591)
37. Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG. 2010. Synergistic effects of ?-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine, 17, 575-580.
38. Mskhiladze L, Kutchukhidze J, Chincharadze D, Delmas F, Elias R, Favel A. 2008. In vitro antifungal and antileishmanial activities of steroidal saponins from Allium leucanthum C Koch-a Caucasian endemic species. Georgian Med News, 154, 39-43.
39. Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47, 3-19. (Pubitemid 32209229)
40. Naderer T, Vince JE, McConville MJ. (2004). Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. Curr Mol Med, 4, 649-665. (Pubitemid 39172369)
41. Nahar M, Jain NK. (2009). Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res, 26, 2588-2598.
42. Ozipek M, Donmez AA, Calis I, Brun R, Ruedi P, Tasdemir D. (2005). Leishmanicidal cycloartane-type triterpene glycosides from Astragalus oleifolius. Phytochemistry, 66, 1168-1173. (Pubitemid 40728313)
43. Park TG, Yong Lee H, Sung Nam Y. (1998). A new preparation method for protein loaded poly (D, L-lactic-co-glycolic acid) microspheres and protein release mechanism study. J Control Release, 55, 181-191. (Pubitemid 28477609)
44. Paul M, Durand R, Boulard Y, Fusai T, Fernandez C, Rivollet D, Deniau M, Astier A. (1998). Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: Implication in the intracellular drug release in Leishmania major infected mice. J Drug Target, 5, 481-490. (Pubitemid 28499682)
45. Peltonen L, Koistinen P, Karjalainen M, Hakkinen A, Hirvonen J. (2002). The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight poly (l)lactide. AAPS PharmSciTech, 3, E32.
46. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli-Allenspach H, Walter E, Merkle HP. (2002). Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake. Pharm Res, 19, 595-601. (Pubitemid 34553665)
47. Piscopo TV, Mallia Azzopardi C. (2007). Leishmaniasis. Postgrad Med J, 83, 649-657. (Pubitemid 44786872)
48. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. (1998). Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm, 24, 1113-1128. (Pubitemid 28546092)
49. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. (2006). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine, 2, 8-21.
50. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. (2004). Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J, 377, 159-169. (Pubitemid 38114443)
51. Roy P, Das S, Bera T, Mondol S, Mukherjee A. (2010). Andrographolide nanoparticles in leishmaniasis: Characterization and in vitro evaluations. Int J Nanomedicine, 5, 1113-1121.
52. Sharif S, O'Hagan DT. 1995. A comparison of alternative methods for the determination of the levels of proteins entrapped in poly (lactideco-glycolide) microparticles. Int J Pharm, 115, 259-263.
53. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X, Zhou H, Xu F. (2009). Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials, 30, 2340-2348.
54. Sinha J, Raay B, Das N, Medda S, Garai S, Mahato SB, Basu MK. (2002). Bacopasaponin C: Critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv, 9, 55-62. (Pubitemid 34171335)
55. Sirtori CR. (2001). Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res, 44, 183-193. (Pubitemid 32889461)
56. Song KC, Lee HS, Choung IY, Cho KI, Ahn Y, Choi EJ. 2006. The effect of type of organic phase solvents on the particle size of poly (D,Llactide-co- glycolide) nanoparticles. Colloids Surf A Physicochem Eng Asp, 276, 162-167. (Pubitemid 43356167)
57. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q, Li Y, Hou S. (2008). PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int J Pharm, 350, 320-329. (Pubitemid 351146679)
58. Sparg SG, Light ME, van Staden J. (2004). Biological activities and distribution of plant saponins. J Ethnopharmacol, 94, 219-243. (Pubitemid 39119924)
59. Suter A, Bommer S, Rechner J. (2006). Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: A review of 5 clinical studies. Adv Ther, 23, 179-190.
60. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade HF Jr. (2004). Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: The use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother, 54, 60-68. (Pubitemid 39028968)
61. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F. (2005). Conjugated poly (D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials, 26, 4189-4195. (Pubitemid 40138665)
62. Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A, Basu MK. (2005). Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target, 13, 161-171. (Pubitemid 40668169)
63. Vauthier C, Bouchemal K. (2009). Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res, 26, 1025-1058.
64. Venier-Julienne MC, Vouldoukis I, Monjour L, Benoit JP. (1995). In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target, 3, 23-29.
65. Vercauteren D, Vandenbroucke RE, Jones AT, Rejman J, Demeester J, De Smedt SC, Sanders NN, Braeckmans K. (2010). The use of inhibitors to study endocytic pathways of gene carriers: Optimization and pitfalls. Mol Ther, 18, 561-569.
66. Vermeersch M, Foubert K, da Luz RI, Van Puyvelde L, Pieters L, Cos P, Maes L. (2009). Selective antileishmania activity of 13,28-epoxyoleanane and related triterpene saponins from the plant families Myrsinaceae, Primulaceae, Aceraceae and Icacinaceae. Phytother Res, 23, 1404-1410.
67. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. (2009). In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: Practical relevance of stage-specific differences. Antimicrob Agents Chemother, 53, 3855-3859.
68. Witasp E, Kupferschmidt N, Bengtsson L, Hultenby K, Smedman C, Paulie S, Garcia-Bennett AE, Fadeel B. (2009). Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. Toxicol Appl Pharmacol, 239, 306-319.
69. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. (2008). Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Deliv Rev, 60, 939-954.
70. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. 2006). Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40, 1-9 (Pubitemid 44415493)
71. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng JX, Kohane DS, Yeo Y. (2009). Intracellular drug delivery by poly (lacticco-glycolic acid) nanoparticles, revisited. Mol Pharm, 6, 190-201.
72. Zhou XY, Fu FH, Li Z, Dong QJ, He J, Wang CH. (2009). Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med, 75, 1580-1585.